Syncom Formulations (India) Ltd
Syncom Formulations (India) is engaged in manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments, Inhalers and Herbals.
- Market Cap ₹ 263 Cr.
- Current Price ₹ 3.37
- High / Low ₹ 4.00 / 0.39
- Stock P/E 10.2
- Book Value ₹ 2.02
- Dividend Yield 0.00 %
- ROCE 12.4 %
- ROE 10.3 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.46% over past five years.
- Company has a low return on equity of 8.85% for last 3 years.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 33 | 45 | 48 | 61 | 54 | 56 | 52 | 43 | 29 | 66 | 84 | |
37 | 31 | 41 | 44 | 58 | 50 | 51 | 48 | 39 | 25 | 54 | 71 | |
Operating Profit | 2 | 2 | 4 | 4 | 3 | 4 | 5 | 4 | 4 | 4 | 12 | 13 |
OPM % | 5% | 5% | 8% | 8% | 5% | 7% | 9% | 8% | 8% | 14% | 19% | 15% |
Other Income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 2 | 2 | 4 | 4 | 3 | 4 | 5 | 4 | 4 | 4 | 13 | 13 |
Tax % | 24% | -8% | 21% | 0% | 30% | 27% | 12% | 22% | 9% | 26% | 26% | 24% |
Net Profit | 2 | 2 | 3 | 4 | 2 | 3 | 4 | 4 | 4 | 3 | 9 | 10 |
EPS in Rs | 0.02 | 0.03 | 0.04 | 0.05 | 0.03 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.12 | 0.13 |
Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
55 | 81 | 76 | 118 | 115 | 151 | 173 | 184 | 185 | 159 | 187 | 206 | 222 | |
51 | 76 | 73 | 110 | 104 | 135 | 155 | 167 | 168 | 147 | 175 | 189 | 189 | |
Operating Profit | 4 | 4 | 3 | 8 | 11 | 16 | 18 | 17 | 16 | 12 | 12 | 17 | 33 |
OPM % | 7% | 5% | 4% | 6% | 9% | 11% | 11% | 9% | 9% | 7% | 6% | 8% | 15% |
Other Income | 3 | 5 | 0 | 1 | 1 | 1 | 1 | 3 | 3 | 4 | 5 | 5 | 5 |
Interest | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Depreciation | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
Profit before tax | 6 | 7 | 0 | 5 | 8 | 14 | 16 | 16 | 16 | 12 | 13 | 17 | 34 |
Tax % | 52% | 36% | 53% | 36% | 33% | 33% | 38% | 36% | 33% | 28% | 12% | 18% | |
Net Profit | 3 | 4 | 0 | 4 | 6 | 9 | 10 | 10 | 11 | 9 | 11 | 14 | 26 |
EPS in Rs | 0.08 | 0.10 | 0.00 | 0.04 | 0.07 | 0.12 | 0.13 | 0.13 | 0.14 | 0.11 | 0.14 | 0.18 | 0.33 |
Dividend Payout % | 12% | 14% | 531% | 38% | 24% | 17% | 16% | 15% | 15% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 3% |
3 Years: | 4% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 7% |
3 Years: | 10% |
TTM: | 98% |
Stock Price CAGR | |
---|---|
10 Years: | 15% |
5 Years: | 9% |
3 Years: | 31% |
1 Year: | 427% |
Return on Equity | |
---|---|
10 Years: | 8% |
5 Years: | 9% |
3 Years: | 9% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 12 | 22 | 22 | 22 | 78 | 78 | 78 | 78 | 78 | 78 | 78 | 78 | |
Reserves | 35 | 43 | 59 | 61 | 65 | 17 | 22 | 31 | 36 | 44 | 55 | 68 | 80 |
Borrowings | 11 | 10 | 7 | 6 | 2 | 3 | 6 | 6 | 12 | 12 | 9 | 2 | 7 |
12 | 28 | 24 | 23 | 33 | 42 | 31 | 61 | 48 | 37 | 32 | 33 | 57 | |
Total Liabilities | 63 | 92 | 113 | 113 | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 222 |
32 | 32 | 47 | 51 | 50 | 50 | 46 | 46 | 85 | 89 | 89 | 93 | 92 | |
CWIP | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 |
Investments | 0 | 0 | 7 | 8 | 7 | 9 | 6 | 23 | 1 | 2 | 2 | 1 | 8 |
31 | 61 | 58 | 54 | 66 | 80 | 85 | 101 | 89 | 79 | 83 | 87 | 122 | |
Total Assets | 63 | 92 | 113 | 113 | 123 | 140 | 138 | 175 | 175 | 171 | 173 | 181 | 222 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | -0 | -1 | 6 | 6 | 0 | 0 | 24 | 17 | -2 | 4 | -1 | |
-2 | -1 | -26 | -5 | -0 | 0 | 1 | -23 | -8 | -2 | 2 | 1 | |
3 | 9 | 22 | -1 | -6 | 0 | 1 | -2 | -2 | -2 | -0 | 0 | |
Net Cash Flow | 0 | 7 | -5 | 1 | -1 | 0 | 2 | -1 | 6 | -6 | 7 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 12% | 13% | 1% | 7% | 10% | 15% | 16% | 15% | 14% | 9% | 9% | 12% |
Debtor Days | 86 | 105 | 112 | 74 | 92 | 71 | 66 | 91 | 91 | 87 | 81 | 77 |
Inventory Turnover | 8.81 | 10.72 | 5.00 | 10.68 | 15.09 | 13.04 | 11.40 | 10.17 | 10.29 | 10.67 | 11.25 | 10.44 |
Documents
Add documentRecent announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Feb
- Submission Of The Standalone Un-Audited Financial Results And Limited Review Report For The Quarter/Nine Months Ended On 31St December, 2020 U/R 33 Of The SEBI (LODR) Regulations, 2015. 12 Feb
- Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Feb
- Board Meeting Intimation for Holding 9/2020-21 Board Meeting For Consideration And Approval Of The Standalone Un-Audited Quarterly Financial Results For The Quarter And Nine Months Ended On 31St December,2020. 3 Feb
- Submission Of The Minutes Of The 1/2020-21 Extra Ordinary General Meeting Held On 12Th January, 2021 Under Regulation 30 Read With Schedule III Of SEBI (LODR) Regulation, 2015. 30 Jan
View all